Introduction {#sec1_1}
============

Giant basal cell carcinomas (GBCCs) measuring more than 5 cm constitute less than 1% of all basal cell carcinomas (BCCs) \[[@B1], [@B2]\]. Due to their large size and tendency to infiltrate neighboring muscle, nerve, and bone, these lesions are often disfiguring and disabling. The presence of 2 coexisting GBCCs in the same individual is rare, with few reported cases \[[@B3], [@B4], [@B5], [@B6]\]. Here we present a patient with 2 GBCCs located symmetrically on the bilateral forearms.

Case Report {#sec1_2}
===========

A 71-year-old Caucasian man presented to the emergency room with 2 large tumors symmetrically distributed on his dorsal forearms. The lesions had been growing slowly for 21 years. The patient did not seek medical treatment; instead he opted for home herbal remedies and salves. He also reported gouging out portions to limit tumor growth. The large bleeding lesions were noted when he underwent a routine medical assessment, and he was referred to the hospital for evaluation.

His past medical history was significant for mild dementia. He denied prior exposure to radiation, immunosuppressive medications, and carcinogens. Physical examination was notable for an alert, oriented, cachectic Caucasian man. On the left dorsal forearm there was a 10 × 13 × 4.5 cm exophytic nodular tumor on an ulcerated base. On the right dorsal forearm was a 6 × 4 cm ulcerated plaque with rolled borders. Both tumors were friable with hemorrhagic exudate and sclerotic perilesional skin (Fig [1](#f1){ref-type="fig"}). No lymphadenopathy was appreciated. Biopsies of both lesions were diagnostic for nodular BCC (Fig [2](#f2){ref-type="fig"}). Magnetic resonance imaging of the left forearm tumor revealed local muscle, nerve, and periosteal invasion. Computed tomography scans of the chest, abdomen, and pelvis showed no evidence of nodal involvement or metastatic disease. Superficial wound cultures of both tumors grew *Pseudomonas aeruginosa* that was treated with intravenous cefepime.

Orthopedic and plastic surgery consultants recommended wide local excision of both tumors followed by skin grafting and reconstruction. The patient consented to removal of the lesions but refused subsequent grafts, stating that they were contrary to his beliefs of natural healing. A psychiatry consult was obtained to assess the patient\'s ability to make medical decisions, and he was found to have capacity. He was discharged in a stable condition to a rehabilitation facility, with outpatient follow-up arranged to discuss nonsurgical treatment options.

Discussion {#sec1_3}
==========

While BCCs are generally small and slow growing, GBCCs are rare, aggressive tumors that often recur and are more likely to metastasize \[[@B7]\]. Though many risk factors for GBCCs are similar to those for BCCs (e.g., Caucasian race, prior history of BCC, and exposure to ultraviolet radiation), a distinct feature of GBCC is a patient\'s neglect of the lesion and a resulting delay in effective intervention \[[@B3], [@B5], [@B8], [@B9]\].

A common trend among cases of GBCC is patients' distrust of contemporary Western medicine \[[@B3], [@B5], [@B8]\]. Previous case reports of multiple GBCCs also described patients with established beliefs in holistic or religious treatments \[[@B3], [@B5], [@B8]\]. In some instances, patients that experienced BCC recurrence after surgical excision were frustrated by the outcome and rejected all further care, leading to progression and death from associated complications \[[@B10]\].

Given the markedly increased risk of metastases and death from GBCC, it is particularly important to recognize and openly address patient concerns regarding treatment options. Establishing a strong physician-patient therapeutic alliance is a critical step in identifying and implementing interventions.

While excision remains the widely acknowledged gold standard of treatment for GBCC \[[@B1], [@B2], [@B7]\], Table [1](#T1){ref-type="table"} summarizes various alternative therapies that have been reported in the medical literature and can be discussed with patients declining first-line surgical modalities \[[@B11], [@B12], [@B13], [@B14], [@B15]\]. Most of these medical therapies are affordable and easily dosed and have an acceptable side effect profile. Treatment involving radiation has historically been reserved for poor surgical candidates \[[@B11], [@B12], [@B13]\]. Vismodegib is a targeted chemotherapy agent that has been shown to halt tumor growth, but it has many side effects \[[@B9]\]. Finally, imiquimod has been used alone or in combination with cryosurgery or acitretin to successfully shrink GBCCs by an unknown mechanism \[[@B6], [@B14], [@B15]\]. In each instance, treating physicians were able to negotiate treatment plans that were consistent with patient beliefs, resulting in compliance and tumor regression.

In conclusion, GBCCs are rare, destructive tumors that are more likely to develop in patients with strong beliefs in complementary and holistic medicine. A discussion and implementation of less invasive alternative therapeutic modalities can be integral to patient survival and improved clinical outcomes.
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![Fungating, friable tumors on the bilateral forearms.](cde-0008-0363-g01){#f1}

![Representative H&E stain of biopsies from the right forearm tumor, demonstrating nodular, pseudopalisading basaloid cells in an infiltrative pattern. A stromal reaction was noted in both lesions.](cde-0008-0363-g02){#f2}

###### 

Successful nonsurgical options for unresectable nonmetastatic GBCCs

  -------------------------------------------------- ------------------------ ----------------------------------------------------------- -------------------------------- -------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Treatment                                          Patient age/sex, years   Reason for nonsurgical intervention                         Location and size of tumor, cm   Stage    Neoadjuvant   Treatment details                                                                                                                           Outcome                                                                                                       Side effects

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Intensity-modulated radiation therapy \[[@B11]\]   59/M                     Poor surgical candidate with COPD, CAD, epilepsy, HTN       Upper back\                      T4N0M0   No            12 MeV 60 Gy total dose, then 9 MeV 20 Gy over 3 months                                                                                     Lesion shrunk to 2--3 cm; minimal involvement of deeper soft tissues; no evidence of recurrence at 5 months   No significant side effects
                                                                                                                                          10 × 10                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Superficial roentgen radiotherapy \[[@B12]\]       66/M                     Refusal of surgical intervention                            Shoulder\                        T4N1M0   No            160 kV 150 Gy total dose over 10 treatments                                                                                                 No recurrence at 1 year and satisfying aesthetic results                                                      No significant side effects
                                                                                                                                          10 × 7                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Chemoradio-therapy \[[@B13]\]                      62/F                     Refusal of surgical intervention                            Face\                            T4N1M1   No            6,000 cGy total dose over 3 weeks plus oral cisplatin and 5-fluorouracil                                                                    No recurrence at 6 months                                                                                     NS
                                                                                                                                          5.5 × 4.5                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Vismodegib \[[@B9]\]                               59/M                     Poor surgical candidate with COPD, CAD, epilepsy, HTN       Upper back\                      T4N0M0   Yes           Continuous for 11 years                                                                                                                     Arrested growth of tumor                                                                                      Dysgeusia, diarrhea, anorexia
                                                                                                                                          10 × 10                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Imiquimod \[[@B14]\]                               51/M                     Unfavorable location                                        Cheek\                           T3N0M0   No            Applied every other day for 8--12 h over 12 weeks                                                                                           No recurrence at 3 years                                                                                      Local irritation, inflammation, edema after 1 week; resolved with prednisone burst and decreased application to every third day
                                                                                                                                          6 × 8                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Imiquimod-cryosurgery combination \[[@B15]\]       54/M                     Patient reluctance, and affected area too large for flap    Frontal scalp\                   T3N0M0   No            2--3 freeze-thaw cycles followed by 5% imiquimod cream after 4 days repeated monthly for 4 cycles                                           No recurrence at 9 months                                                                                     NS
                                                                                                                                          6 × 8                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Acitretin-imiquimod combination \[[@B6]\]          68/F                     Refusal of surgical intervention                            Chest\                           NS       Yes           Daily 25 mg/day oral acitretin and 5% imiquimod cream for 6 months; eventual surgery and radiotherapy (200 cGy in 30 doses), respectively   No recurrence at 8 years                                                                                      Malaise; resolved with decreased imiquimod dose
                                                                                                                                          18 × 11\                                                                                                                                                                                                                                                                                                          
                                                                                                                                          8 × 4                                                                                                                                                                                                                                                                                                             

                                                     63/M                     Unfavorable location and refusal of surgical intervention   Cheek\                           NS       Yes                                                                                                                                                       No recurrence at 2 years                                                                                      Local inflammation
                                                                                                                                          10 × 7                                                                                                                                                                                                                                                                                                            
  -------------------------------------------------- ------------------------ ----------------------------------------------------------- -------------------------------- -------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HTN, hypertension; NS, not specified.
